Breaking News Instant updates and real-time market news.

REV

Revlon

$22.53

0.45 (2.04%)

, RLGY

Realogy

$18.21

0.45 (2.53%)

08:45
11/06/18
11/06
08:45
11/06/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Revlon (REV) 53.00% +0.41, Realogy (RLGY) 1.62% +0.28, Ferrari (RACE) 0.49% +0.09, Direxion Junior Gold (JNUG) 2.82% +0.08, HUYA (HUYA) 14.60% +0.07, Schlumberger (SLB) 0.35% +0.06, Barrick Gold (ABX) 0.45% +0.06, JPMorgan (JPM) 0.28% +0.03, iQiyi (IQ) 1.95% +0.03, and ProShares Ultra VIX Short Term Futures (UVXY) 8.76% +0.02.

REV

Revlon

$22.53

0.45 (2.04%)

RLGY

Realogy

$18.21

0.45 (2.53%)

RACE

Ferrari

$117.51

-1.98 (-1.66%)

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$7.89

0.14 (1.81%)

HUYA

Huya

$19.59

-0.275 (-1.38%)

SLB

Schlumberger

$51.98

0.6 (1.17%)

ABX

Symbol changed to GOLD

$13.24

0.06 (0.46%)

JPM

JPMorgan

$109.08

0.79 (0.73%)

IQ

iQIYI

$21.16

0.03 (0.14%)

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$57.08

-0.63 (-1.09%)

  • 06

    Nov

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 09

    Nov

  • 12

    Nov

  • 26

    Feb

REV Revlon
$22.53

0.45 (2.04%)

03/16/18
JEFF
03/16/18
NO CHANGE
Target $20
JEFF
Hold
Revlon fundamentals continue to weaken, says Jefferies
Jefferies analyst Stephanie Wissink says her fundamental thesis remains unchanged on Revlon following last night's Q4 results. Fundamental trends in Revlon's lead markets continue to weaken, costs to compete are rising, and the profit recovery continues to be delayed, Wissink writes in a post-earnings research. She expects merger synergies will benefit the model, but notes assumptions around core brand reinvestment continue to move higher. The analyst keeps a Hold rating on Revlon with a $20 price target.
RLGY Realogy
$18.21

0.45 (2.53%)

12/15/17
JPMS
12/15/17
DOWNGRADE
Target $28
JPMS
Underweight
Realogy downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Anthony Paolone downgraded Realogy Holdings to Underweight and lowered his price target for the shares to $28 from $30 in conjunction with his 2018 REIT outlook.
11/05/18
PIPR
11/05/18
DOWNGRADE
Target $19
PIPR
Neutral
Realogy downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Jason Deleeuw downgraded Realogy Holdings to Neutral and lowered his price target for the shares to $19 from $32. The analyst expects "persistent headwinds" of weak home sales volume and "intense" competition for agents. While he does not expect a "housing collapse," Deleeuw does expect "a time correction on home sales/price trends." The weak volume trends will eventually return to an up-cycle, but the intense competitive environment for agents will likely remain "given well-capitalized newer brokers that have shifted economic commission splits more in favor of agents vs. brokers," the analyst tells investors in a research note.
02/27/18
SPHN
02/27/18
NO CHANGE
Target $33
SPHN
Overweight
Stephens buyers of Realogy following earnings report
Stephens analyst John Campbell said he would be buying Realogy shares following the company's Q4 report, Q1 guidance and 2018 commentary, noting that management was "adamant" on the earnings call that Q1 trends did not fully reflect their view of EBITDA progress in the rest of the fiscal year. The company thinks EBITDA in Q2-Q4 of FY18 will be flat to better year-over-year, noted Campbell, who keeps an Overweight rating and $33 price target on Realogy shares.
02/28/18
DBAB
02/28/18
NO CHANGE
Target $35
DBAB
Buy
Realogy shares to build on yesterday's rally, says Deutsche Bank
Deutsche Bank analyst Kevin McVeigh expects shares of Realogy to be build yesterday's rally in the coming weeks and months. In a post-earnings research note titled "Buy non distressed at distressed value," the analyst maintains a Buy rating on the shares with a $35 price target. The analyst looks for "multiple positive 2018 catalysts", namely the Cartus restructuring, split normalization and new CEO, to drive upside to the shares.
RACE Ferrari
$117.51

-1.98 (-1.66%)

10/11/18
10/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Huntington Ingalls (HII) downgraded to Sell from Neutral at Goldman Sachs with analyst Noah Poponak saying the company's pace of growth may not support current valuation levels. 2. Ferrari (RACE) downgraded to Hold from Buy at Jefferies with analyst Philippe Jean Houchois saying he re-based his expectations lower to reflect higher upfront investments and a lower quality of earnings as management's new strategy of less volume and more exclusivity takes hold. 3. Valero (VLO) downgraded to Hold from Buy at Tudor Pickering. 4. TransDigm (TDG) downgraded to Neutral from Outperform at Baird with analyst Peter Arment saying the Esterline (ESL) deal is a shift in the company's strategy in buying a "fixer-up asset" with significantly below average returns that will take time to improve. He believes it will be an overhang on the stock near-term. Arment maintained his $365 price target on TransDigm shares. 5. Tata Motors (TTM) downgraded to Hold from Buy at HSBC with analyst Amyn Pirani saying while the company's India business has surprised positively, Jaguar Land Rover's volumes have continued to decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/18
BOFA
10/16/18
NO CHANGE
BOFA
Ferrari, PayPal added to US 1 List, ADP, NetApp removed at BofA/Merrill
10/10/18
10/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Discovery (DISCA) upgraded to Outperform from Neutral at Credit Suisse with analyst Doug Mitchelson saying he has reviewed the company's Nielsen ratings trends in detail, discussed the company's ad execution with industry contacts and recalibrated distribution trends leading to an increase in his U.S. revenue forecast and increased confidence in his above-Street EBITDA estimates. 2. McDonald's (MCD) upgraded to Buy from Neutral at Guggenheim. 3. Ferrari (RACE) upgraded to Hold from Sell at Societe Generale with analyst Stephen Reitman saying the final version of the mid-term FY22 plan shared by new CEO Louis Camilleri in September broadly repeats the key financial goals first stated in February, but the manner as to how these will be achieved appears to have fundamentally altered. 4. Intuitive Surgical (ISRG) upgraded to Overweight from Neutral at Piper Jaffray with analyst JP McKim saying a survey of doctors from various specialties came back favorable for robotics and confirms that robotic surgery penetration is going "much higher." 5. Tile Shop (TTS) assumed with a Buy from Neutral at Citi with analyst Geoffrey Small saying the hard-surface flooring sector is attractive given its favorable growth profile, highly-fragmented structure and because it carries very little threat of e-commerce disruption. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/18
JEFF
10/11/18
DOWNGRADE
Target $132
JEFF
Hold
Ferrari downgraded to Hold from Buy at Jefferies
Jefferies analyst Philippe Jean Houchois downgraded Ferrari to Hold and lowered his price target for the shares to $132 from $155. The analyst re-based his expectations lower to reflect higher upfront investments and a lower quality of earnings as management's new strategy of less volume and more exclusivity takes hold.
JNUG Direxion Daily Jr Gld Mnrs Bull 3X Shrs
$7.89

0.14 (1.81%)

HUYA Huya
$19.59

-0.275 (-1.38%)

10/29/18
SBSH
10/29/18
INITIATION
Target $26
SBSH
Buy
Huya initiated with a Buy at Citi
Citi started Huya with a Buy rating and $26 price target.
08/14/18
BNCH
08/14/18
NO CHANGE
Target $140
BNCH
Buy
YY price target lowered to $140 from $168 at Benchmark
Benchmark analyst Fawne Jiang maintained a Buy rating on YY (YY), but lowered her price target to $140 from $168 following the company's "solid" Q2 earnings report and Q3 revenue guidance that "slightly" trailed consensus estimates due to softness in YY Live. In a research note to investors, the analyst says that increased investments in Huya (HUYA), as well as a potential rise of content cost and S & M spending in YY Live, could weigh on margins in the coming quarters, and she views YY as a value play for longer-term oriented investors.
10/01/18
EGHT
10/01/18
UPGRADE
EGHT
Hold
HUYA upgraded to Hold from Sell at 86 Research
09/04/18
LYON
09/04/18
INITIATION
LYON
Outperform
HUYA initiated with an Outperform at CLSA
SLB Schlumberger
$51.98

0.6 (1.17%)

10/22/18
FBCO
10/22/18
NO CHANGE
Target $71
FBCO
Outperform
Schlumberger price target lowered to $71 from $82 at Credit Suisse
Credit Suisse analyst Jim Wicklund lowered his price target for Schlumberger to $71 from $82 following quarterly results. The analyst reiterates an Outperform rating on the shares.
10/17/18
BOFA
10/17/18
NO CHANGE
BOFA
BofA/Merrill reinstating Oilfield Services coverage with Halliburton as top pick
BofA analyst Chase Mulvehill reinstated coverage of U.S. onshore and diversified oilfield service, or OFS, saying he has a bullish near-to-medium term view on the sector. The analyst notes that OFS should outperform thanks to rising oil prices that should lead to "solid" cash flows across the sector. Mulvehill further anticipates investment to increase across the industry, with North America land E&P spending surprising to the upside and U.S. onshore D&C spending rising nearly 20%. The analyst also sees "Permian pipeline relief" adding to the benefits with exposure to the basin. Mulvehill's Top Pick is Halliburton (HAL), and his other Buy-rated names include Baker Hughes (BHGE), C&J Energy Services (CJ), FTS International (FTSI), Keane Group (FRAC), Nabors Industries (NBR), Nine Energy Service (NINE), Patterson-UTI Energy (PTEN), ProPetro Holdings Corp (PUMP), and Schlumberger (SLB).
10/17/18
BOFA
10/17/18
INITIATION
Target $73
BOFA
Buy
Schlumberger initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Chase Mulvehill initiated Schlumberger with a Buy rating and a price target of $73.
10/12/18
SPHN
10/12/18
INITIATION
Target $65
SPHN
Equal Weight
Schlumberger initiated with an Equal Weight at Stephens
Stephens analyst Tommy Moll initiated Schlumberger with an Equal Weight rating and $65 price target, stating that while he anticipates revenue growth both internationally and in North America in 2019, overly optimistic international expectations and the potential drag from North America on profitability put 2019 earnings at risk.
ABX Symbol changed to GOLD
$13.24

0.06 (0.46%)

10/22/18
10/22/18
DOWNGRADE

Neutral
Barrick Gold downgraded to Neutral on valuation at Macquarie
As previously reported, Macquarie downgraded Barrick Gold (ABX) to Neutral from Outperform. Analyst Michael Siperco said shares have outperformed since the merger with Randgold (GOLD) was announced and are trading at fair value.
09/25/18
09/25/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly: TENARIS DOUBLE UPGRADED TO BUY: BofA Merrill Lynch analyst Joao Vicor Lorenzi double upgraded Tenaris (TS) to Buy from Underperform and raised his price target on shares to $40 from $30. Lorenzi expects Tenaris to benefit from a sustained, broad based recovery in its end markets that should result in a muli-year period of strong earnings momentum. The analyst also said the recent pullback in shares has created a compelling buying opportunity. In late morning trading, Tenaris shares are higher by 5.3%. CITI UPGRADES BARRICK TO BUY: Citi analyst Alexander Hacking upgraded Barrick Gold (ABX) to Buy from Neutral and raised his price target for the shares to $14 from $11, saying the company's acquisition of Randgold (GOLD) is a win for Barrick on two levels. One, Barrick management gets an upgrade to the most successful CEO in the sector, which adds "significant credibility" to its turnaround. Two, the deal solidifies Barrick's capital allocation by removing the acquisition overhang and accelerating assets sales, the analyst added. RAYMOND JAMES CUTS INTEL TO UNDERPERFORM: Raymond James analyst Chris Caso downgraded Intel (INTC) to Underperform from Market Perform based on sector cyclical concerns following checks in Asia. Caso's checks indicate there has been a negative sentiment shift during the month of September among suppliers, with several trends clearly worsening. The analyst has concluded that the the semiconductor sector has entered a cyclical downturn and has made a broad call to downgrade nearly all of his stocks under coverage. For Intel, Caso said the company's CPU shortages are well-know, but recent checks suggest shortages on some new high margin SKUs, which will limit near-term upside. SIRIUS CUT TO NEUTRAL FOLLOWING PANDORA ACQUISITION: Credit Suisse analyst Brian Russo downgraded Sirius XM (SIRI) to Neutral and lowered his price target for the shares to $7.50 from $8.50. The company's acquisition of Pandora Media (P) "changes the story," Russo said. The analyst believes the opportunities and potential synergies between the two companies, as well as management's capital deployment intentions, are "unclear at this time." Further, Russo thinks shares of Sirius XM could be range-bound through the deal's expected close in Q1 of 2019. BENCHMARK STARTS CANOPY WITH A BUY: Benchmark analyst Mike Hickey initiated Canopy Growth (CGC) with a Buy rating and C$100 price target, citing Canopy's early leadership in the medical cannabis market and upcoming legalization of recreational cannabis in Canada and the meaningful investment from Constellation Brands (STZ). That investment accelerates the ongoing build-out of its international production and distribution operations and domestic retail infrastructure to meet rapidly growing global demand, Hickey said.
09/26/18
RBCM
09/26/18
UPGRADE
RBCM
Sector Perform
Randgold upgraded to Sector Perform at RBC Capital on Barrick Gold merger offer
As reported earlier, RBC Capital analyst James Bell upgraded Randgold (GOLD) to Sector Perform from Underperform and raised his price target to GBp 5,000 from GBp 4,500 after an offer from Barrick Gold (ABX) at a valuation in line with the proposed share ratio of the deal. The analyst contends that the purchase would be positive for the company and believes that no further premium is needed, adding he has heard little in terms of a pushback from Randgold even though 2/3rd of the shareholder vote is needed to approve the transaction.
10/22/18
MACQ
10/22/18
DOWNGRADE
MACQ
Neutral
Barrick Gold downgraded to Neutral from Outperform at Macquarie
JPM JPMorgan
$109.08

0.79 (0.73%)

10/16/18
JANY
10/16/18
NO CHANGE
JANY
Buy
Janney Montgomery Scott says On Deck's new unit hints at new bank partnerships
After On Deck Capital (ONDK) announced earlier that it has created a new wholly owned subsidiary, ODX, that will provide technology and other services to banks looking to lend online to small businesses, Janney Montgomery Scott analyst John Rowan said he sees this as the logical step before the company announces one or more new bank partnerships. While he thinks the company's lone existing bank partnership, with JPMorgan (JPM), is not a profit center, Rowan believes that the economics could improve as each new bank partner comes on-board and he thinks ODX could eventually become a profit center for On Deck. He maintains a Buy rating on the stock.
10/15/18
BMOC
10/15/18
NO CHANGE
Target $124
BMOC
Market Perform
JPMorgan price target raised to $124 from $118 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on JPMorgan to $124 after its Q3 earnings beat driven by lower than expected loan loss provision. The analyst notes that financials are "cheap again" in spite of the rising interest rates which are positive for net interest margins, better employment which is positive for credit, and regulatory relief which is positive for their capital position. Fotherinham also keeps his Market Perform rating on JPMorgan, saying its two-year forward earnings multiple is "only slightly" below its long-term historical average.
09/25/18
WOLF
09/25/18
INITIATION
Target $140
WOLF
Outperform
JPMorgan initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated JPMorgan with an Outperform and $140 price target.
10/03/18
BERN
10/03/18
NO CHANGE
BERN
Amazon to be accelerant of disruption coming for healthcare, says Bernstein
Bernstein analyst Lance Wilkes believes disruption is coming for healthcare and that Amazon (AMZN) will be an accelerant of this disruption. Further, the analyst sees a parallel with the fast changes in health insurance which took place in the 90's, when health insurance changed from 90% indemnity to 80% managed care within ten years. Wilkes thinks Amazon is developing a series of business strategies for entering healthcare market segments, namely directly entering online pharmacy, creating a disruptor in the employer healthcare space through its venture with Berkshire (BRK.A) and JPMorgan (JPM), and entering digital consumer healthcare spaces including using Alexa for consumer engagement and behavior modification.
IQ iQIYI
$21.16

0.03 (0.14%)

10/12/18
OPCO
10/12/18
NO CHANGE
Target $265
OPCO
Outperform
Baidu price target cut to $265 from $295 at Oppenheimer
Oppenheimer analyst Jason Helfstein reiterated an Outperform rating on Baidu (BIDU) but cut his price target to $265 from $295 citing valuation, higher near-term investments, as well as the firm's recently-lowered price target for Ctrip (CTRP) and the recent downward movement of iQIYI (IQ) shares. In a research note to investors, Helfstein contends that investors' concern around macro/trade war and the risk of Google's (GOOG, GOOGL) re-entrance into China are "overstated," especially the Google piece, due to increased U.S. government scrutiny.
10/31/18
FBCO
10/31/18
UPGRADE
FBCO
Outperform
iQIYI upgraded to Outperform from Neutral at Credit Suisse
10/08/18
10/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Huntsman (HUN) initiated with an Underweight at Barclays. 2. NIO Inc. (NIO) initiated with a Buy at Deutsche Bank and a Neutral at Goldman Sachs. 3. Cabot (CBT) initiated with an Overweight at Barclays. 4. Auris Medical (EARS) initiated with a Buy at Euro Pacific. 5. iQIYI (IQ) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/29/18
EGHT
10/29/18
UPGRADE
EGHT
Hold
iQIYI upgraded to Hold from Sell at 86 Research
UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$57.08

-0.63 (-1.09%)

TODAY'S FREE FLY STORIES

DDAIF

Daimler AG

$0.00

(0.00%)

04:55
02/18/19
02/18
04:55
02/18/19
04:55
Conference/Events
Daimler AG management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 19

    Feb

03:05
02/18/19
02/18
03:05
02/18/19
03:05
General news
FX Update: The Yen traded softer amid a risk-on backdrop »

FX Update: The Yen traded…

01:55
02/18/19
02/18
01:55
02/18/19
01:55
Conference/Events
Morgan Stanley Asian strategists to hold an analyst/industry conference call »

Asian Strategist Garner,…

ETFC

E-Trade

$47.45

0.88 (1.89%)

17:33
02/17/19
02/17
17:33
02/17/19
17:33
Conference/Events
E-Trade to hold Education Day »

Education Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

PFE

Pfizer

$42.41

0.45 (1.07%)

12:56
02/17/19
02/17
12:56
02/17/19
12:56
Hot Stocks
Pfizer, EMD Serono announce publication of Phase 3 data for BAVENCIO plus INLYTA »

Merck KGaA, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 18

    May

MRK

Merck

$79.84

0.9 (1.14%)

, PFE

Pfizer

$42.41

0.45 (1.07%)

12:48
02/17/19
02/17
12:48
02/17/19
12:48
Hot Stocks
Merck presents results from Phase 3 KEYNOTE-426 study »

Merck (MRK) announced…

MRK

Merck

$79.84

0.9 (1.14%)

PFE

Pfizer

$42.41

0.45 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 11

    Apr

  • 18

    May

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

12:42
02/17/19
02/17
12:42
02/17/19
12:42
Hot Stocks
Aveo Pharmaceuticals presents TIVO-3 trial topline results »

Aveo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDM

Aradigm

$0.00

(0.00%)

12:34
02/17/19
02/17
12:34
02/17/19
12:34
Hot Stocks
Aradigm announces plans for reorganization under Chapter 11 »

Aradigm has filed for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

, XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

13:26
02/16/19
02/16
13:26
02/16/19
13:26
Periodicals
Amazon a risk for almost every stock/sector, Barron's says »

Amazon (AMZN) is eating…

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

KR

Kroger

$29.50

0.54 (1.86%)

FAST

Fastenal

$62.97

0.61 (0.98%)

GWW

Grainger

$316.63

4.9 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.